Alterity Therapeutics Receives Positive FDA Feedback on ATH434 CMC Meeting for Phase 3 MSA Program

Alterity Therapeutics announced positive feedback from a second Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). This specific meeting focused on chemistry, manufacturing, and control (CMC) elements. The FDA endorsed Alterity’s plans for the manufacture and testing of ATH434 for both the upcoming Phase 3 trial and potential future commercialization. This regulatory alignment follows a previous Type C meeting in March 2026 that covered clinical pharmacology and non-clinical development. ATH434 is the company’s lead asset, which has previously demonstrated efficacy in randomized Phase 2 trials for MSA. The successful CMC alignment supports the company's readiness for Phase 3 initiation, with manufacturing scale-up currently progressing in parallel. Alterity remains on track for an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the pivotal trial design.